Metsera, Inc. (Nasdaq: MTSR) ('Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...

ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...